- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06560385
Soulagement de l'alopécie chez les patientes atteintes d'un cancer du sein à l'aide d'une formule symbiotique
Un essai pilote, en double aveugle, randomisé et contrôlé par placebo sur l'efficacité d'une formule symbiotique (BLHK03) pour soulager l'alopécie induite par la chimiothérapie (CIA) chez les patientes atteintes d'un cancer du sein
This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In a mice study, it was shown that oral administration of a probiotic isolated from healthy faeces, B. longum HK003, has protective effects against alopecia related to chemotherapy. Mice were treated with 100 mg/kg cyclophosphamide (CYP) once monthly, for 4 months. The CYP-treated mice were then treated with B. longum HK003 for 14 days. Results showed that B. longum treatment significantly enhanced skin thickness histologically. In the subcutis, the quantity and size of anagen follicles were increased, whilst the quantity of atrophic follicles were decreased.
Currently, there is no documentation of potential probiotic-drug interactions in breast cancer patients undergoing chemotherapy. A previous randomized controlled trial reported no adverse event associated with the use of synbiotics in breast cancer patients during the treatment period(9). Beneficial effects on chemotherapy-induced fatigue and abnormal stool consistency were also observed in subjects receiving synbiotics(9).
Biotin is a water-soluble vitamin that is naturally present in some food and available as a dietary supplement for healthy hair and nails due to its role in keratin production. Most healthy individuals achieve adequate intake of biotin through a well-balanced diet. Current recommendation for biotin by the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine stated that the daily adequate intake (AI) for adults is 30 mcg/day. Although biotin has been widely used as dietary supplement, data on the actual benefit of its effect on hair growth is limited(10).
The use of B. longum HK003 in alleviating chemotherapy-induced alopecia in breast cancer patients has not been explored. This pilot, double-blind, randomised, placebo-controlled trial aims to explore on the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Hong Kong, Hong Kong
- GenieBiome Limited
-
Hong Kong, Hong Kong
- Heal Medical
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer
- Planned chemotherapy including an anthracycline or taxane to be completed within 6 months
- Mentally capable to participate in the study and provide informed consent
Exclusion Criteria:
- Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline
- History of hair transplantation, psoriasis or severe scalp infection
- Undergoing or plan to receive scalp cooling
- Plan for immunotherapy
- Known pregnancy or lactating
- Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions
- Use of antibiotics, probiotics or prebiotics one month prior to enrolment
- No other alternative or complementary treatment for the cancer condition that may affect the gut microbiome analysis
- History of allergy to probiotics or lactose
- History of chemotherapy for other conditions
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Active arm
Subjects will receive 1 sachet of BLHK03 daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy. |
BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds |
|
Comparateur placebo: Placebo arm
Subjects will receive 1 sachet of active placebo daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy. |
Active placebo contains 5mcg of Vitamin B7 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The proportion of subjects with a score of ≤ 2 on the Dean scale (corresponding to hair loss ≤ 50%) 2 months after the final dose of chemotherapy
Délai: Baseline to 2 months after the final dose of chemotherapy
|
The change of Dean scale (corresponding to hair loss) after chemotherapy compared to baseline. Score 0 means no hair loss and score 4 means all hair is fallen down. |
Baseline to 2 months after the final dose of chemotherapy
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Gut microbial change at 2 months after the final dose of chemotherapy
Délai: Baseline to 2 months after the final dose of chemotherapy
|
The change of gut microbiota composition at 2 months after the final dose of chemotherapy compared to baseline |
Baseline to 2 months after the final dose of chemotherapy
|
|
Adverse event rates related to the study during the study period
Délai: Baseline to 2 months after the final dose of chemotherapy
|
The adverse events reported throughout the study |
Baseline to 2 months after the final dose of chemotherapy
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Jessica Ching, PhD, GenieBiome Limited
Publications et liens utiles
Publications générales
- Lam S, Zhang J, Yang K, Chu LC, Zhu W, Tang W, Chan FKL, Chan PKS, Wu WKK, Ng SC. Modulation of gut microbiota impacts diet-induced and drug-induced alopecia in mice. Gut. 2022 Nov;71(11):2366-2369. doi: 10.1136/gutjnl-2021-326320. Epub 2022 Jan 5. No abstract available.
- Khazaei Y, Basi A, Fernandez ML, Foudazi H, Bagherzadeh R, Shidfar F. The effects of synbiotics supplementation on reducing chemotherapy-induced side effects in women with breast cancer: a randomized placebo-controlled double-blind clinical trial. BMC Complement Med Ther. 2023 Sep 26;23(1):339. doi: 10.1186/s12906-023-04165-8.
- Patel DP, Swink SM, Castelo-Soccio L. A Review of the Use of Biotin for Hair Loss. Skin Appendage Disord. 2017 Aug;3(3):166-169. doi: 10.1159/000462981. Epub 2017 Apr 27.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- BCIA Study
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .